HRP20090490T1 - Processes for preparing eptifibatide and pertinent intermediate compounds - Google Patents

Processes for preparing eptifibatide and pertinent intermediate compounds

Info

Publication number
HRP20090490T1
HRP20090490T1 HR20090490T HRP20090490T HRP20090490T1 HR P20090490 T1 HRP20090490 T1 HR P20090490T1 HR 20090490 T HR20090490 T HR 20090490T HR P20090490 T HRP20090490 T HR P20090490T HR P20090490 T1 HRP20090490 T1 HR P20090490T1
Authority
HR
Croatia
Prior art keywords
eptifibatide
processes
fragment
intermediate compounds
preparing
Prior art date
Application number
HR20090490T
Other languages
English (en)
Croatian (hr)
Inventor
Ho Guojie
D. Paone Antoinette
Forni Luciano
Detollenaere Catherine
Bonnett Brice
Original Assignee
Millennium Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals filed Critical Millennium Pharmaceuticals
Publication of HRP20090490T1 publication Critical patent/HRP20090490T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Combined Means For Separation Of Solids (AREA)
  • Indole Compounds (AREA)
HR20090490T 2004-04-08 2009-09-15 Processes for preparing eptifibatide and pertinent intermediate compounds HRP20090490T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56045304P 2004-04-08 2004-04-08
PCT/US2005/011873 WO2005100381A2 (en) 2004-04-08 2005-04-08 Processes for preparing eptifibatide and pertinent intermediate compounds

Publications (1)

Publication Number Publication Date
HRP20090490T1 true HRP20090490T1 (en) 2009-10-31

Family

ID=34956145

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20090490T HRP20090490T1 (en) 2004-04-08 2009-09-15 Processes for preparing eptifibatide and pertinent intermediate compounds
HR20110812T HRP20110812T1 (en) 2004-04-08 2011-11-02 Processes for preparing eptifibatide and pertinent intermediate compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20110812T HRP20110812T1 (en) 2004-04-08 2011-11-02 Processes for preparing eptifibatide and pertinent intermediate compounds

Country Status (21)

Country Link
US (2) US7674768B2 (es)
EP (2) EP2204383B1 (es)
JP (2) JP4926942B2 (es)
KR (1) KR101238133B1 (es)
CN (1) CN1972960B (es)
AT (2) ATE519781T1 (es)
AU (1) AU2005233603B2 (es)
CA (1) CA2562157C (es)
CY (2) CY1109357T1 (es)
DE (1) DE602005014956D1 (es)
DK (2) DK1735345T3 (es)
ES (2) ES2328713T3 (es)
HK (2) HK1099313A1 (es)
HR (2) HRP20090490T1 (es)
ME (2) ME01063B (es)
MX (1) MXPA06011904A (es)
PL (2) PL1735345T3 (es)
PT (2) PT1735345E (es)
RS (2) RS51182B (es)
SI (2) SI2204383T1 (es)
WO (1) WO2005100381A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1709065T3 (da) * 2004-10-04 2010-08-23 Novetide Ltd Modion-bytningsfremgangsmåde til peptider
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
KR101257330B1 (ko) * 2008-02-06 2013-04-23 바이오콘 리미티드 펩타이드 정제 방법
WO2009150657A1 (en) * 2008-06-09 2009-12-17 Natco Pharma Limited Improved process for preparation of eptifibatide by fmoc solid phase synthesis
CN101538314B (zh) * 2009-01-13 2012-10-03 深圳翰宇药业股份有限公司 一种纯化爱啡肽的方法
CN101747412A (zh) * 2009-12-30 2010-06-23 江苏诺泰制药技术有限公司 一种依替非巴肽的合成制备工艺
CN102174081B (zh) * 2011-03-09 2013-05-29 杭州华津允上医药有限公司 埃替非巴肽及其前体的制备方法
CN102827249A (zh) * 2011-06-14 2012-12-19 江苏豪森医药集团连云港宏创医药有限公司 一种依替巴肽的液相合成方法
CN103408637B (zh) 2013-06-27 2015-12-02 深圳翰宇药业股份有限公司 一种爱啡肽的制备方法
CN104710509B (zh) * 2013-12-11 2018-01-02 深圳翰宇药业股份有限公司 一种爱啡肽的制备方法
CN108250265A (zh) * 2016-12-29 2018-07-06 北京中科亚光生物科技有限公司 一种合成含有分子内二硫键的多肽的新工艺
CN110894212B (zh) * 2018-08-24 2021-06-04 翰宇药业(武汉)有限公司 一种合成依替巴肽硫醚的方法
CN109251234A (zh) * 2018-10-08 2019-01-22 重庆科脉生物化工有限公司 一种抗血小板聚集药物爱啡肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2616785B1 (fr) * 1987-06-19 1989-10-06 Solvay Composes guanidiniques comprenant un ion tetraphenylborate substitue et procede d'obtention de ces composes et utilisation des composes lors de la synthese peptidique
US5686568A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregration inhibitors
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
BE1007184A3 (fr) * 1993-06-18 1995-04-18 Solvay Procede de preparation d'un amide d'alpha-aminoacide, utilisable en synthese peptidique.
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
WO2003093302A2 (en) * 2002-05-03 2003-11-13 Avecia Limited Process for the synthesis of peptides amides by side-chain attachement to a solid phase
DE04759123T1 (de) * 2003-04-07 2005-08-18 Novetide Ltd. Verfahren zur herstellung cyclischer peptide
NL2000126C2 (nl) 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.

Also Published As

Publication number Publication date
RS51182B (sr) 2010-10-31
CA2562157C (en) 2013-09-10
ME01063B (me) 2012-10-20
CN1972960A (zh) 2007-05-30
US7674768B2 (en) 2010-03-09
US20060036071A1 (en) 2006-02-16
ME01260B (me) 2013-06-20
EP1735345A2 (en) 2006-12-27
CY1111904T1 (el) 2015-11-04
HK1145691A1 (en) 2011-04-29
EP2204383A1 (en) 2010-07-07
KR20070015537A (ko) 2007-02-05
ATE433997T1 (de) 2009-07-15
HRP20110812T1 (en) 2011-11-30
DK1735345T3 (da) 2009-10-26
HK1099313A1 (en) 2007-08-10
RS51929B (en) 2012-02-29
WO2005100381A2 (en) 2005-10-27
PT2204383E (pt) 2011-10-31
CN1972960B (zh) 2010-05-12
AU2005233603B2 (en) 2011-07-21
ATE519781T1 (de) 2011-08-15
EP2204383B1 (en) 2011-08-10
PL2204383T3 (pl) 2012-01-31
US20100105609A1 (en) 2010-04-29
AU2005233603A1 (en) 2005-10-27
JP4926942B2 (ja) 2012-05-09
PT1735345E (pt) 2009-09-11
JP2012111756A (ja) 2012-06-14
DE602005014956D1 (de) 2009-07-30
CA2562157A1 (en) 2005-10-27
JP2007537161A (ja) 2007-12-20
ES2328713T3 (es) 2009-11-17
KR101238133B1 (ko) 2013-03-04
MXPA06011904A (es) 2007-01-25
ES2369872T3 (es) 2011-12-07
CY1109357T1 (el) 2014-07-02
DK2204383T3 (da) 2011-10-17
EP1735345B1 (en) 2009-06-17
SI2204383T1 (sl) 2011-11-30
SI1735345T1 (sl) 2010-01-29
WO2005100381A3 (en) 2006-07-27
PL1735345T3 (pl) 2009-12-31

Similar Documents

Publication Publication Date Title
HRP20110812T1 (en) Processes for preparing eptifibatide and pertinent intermediate compounds
MY147633A (en) Preparation of azoxystrobin
SG170729A1 (en) Processes and intermediates for preparing steric compounds
IL190333A (en) Process and intermediates for the synthesis of caspofungin
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
WO2010036329A3 (en) Process for making quinolone compounds
WO2010070667A3 (en) Process and intermediates for the preparation of 7-( (3-chloro-6-methyl-5,5-dioxo-6,ll-dihydrodibenzo (c, f) (1,2) thiazepin-11-yd amino) heptanoate
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
TW200740729A (en) Methods for preparing glutamic acid derivatives
TW200624435A (en) Process for preparing iridium(Ⅲ) ketoketonates
IL206570A0 (en) Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
WO2005054175A3 (en) New process for the preparation of nitrooxyderivatives of paracetamol
ATE332307T1 (de) Wachstumhormonsekretionsförderer
MY148560A (en) Process for preparing phosphonates having alcoholic hydroxyl group
WO2012070896A3 (en) Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid
MXPA05007696A (es) Modificacion cristalina de un complejo de manganeso.
MX2009008093A (es) Procedimientos para la preparacion de compuestos de urea sustituidos con piperidinilo.
WO2013093705A3 (en) Improved processes for preparing peptide conjugates and linkers
SI1572615T1 (sl) Postopek za sintezo peptidov ki vsebujejo hidroksi prolinsko substrukturo
TW200724523A (en) The manufacturing method of prostaglandin F derivatives and the novel intermediates thereof
WO2008051489A3 (en) Salt forms of substituted benzothienyl compounds
TW200637495A (en) Novel composite for inhibiting algae growth and use thereof